Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials


A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Comparing the Efficacy and Safety of PMI-150 (Intranasal Ketamine) to Placebo as an Analgesic for the Treatment of Breakthrough Pain in Cancer Patients


To see complete record on clinicaltrials.gov, please visit this link

Id: NCT00492388

Organisation Name: Hospira, now a wholly owned subsidiary of Pfizer

Overal Status: Terminated

Start Date: June 2007

Last Update: January 11, 2012

Lead Sponsor: Hospira, now a wholly owned subsidiary of Pfizer

Brief Summary: To assess the safety and efficacy of PMI-150 (Intranasal Ketamine) as an analgesic for the treatment of breakthrough pain in cancer patients.

Conditions:
  • Pain
  • Cancer


Total execution time in seconds: 0.20886206626892